Cancer of unknown primary sites: What radiologists need to know and what oncologists want to know

American Journal of Roentgenology

Volumn 200, Issue 3, 2013, Pages 484-492

  Kim, Kyung Won ^a,b   Krajewski, Katherine M ^a   Jagannathan, Jyothi P ^a   Nishino, Mizuki ^a   Shinagare, Atul B ^a   Hornick, Jason L ^c   Ramaiya, Nikhil H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Asan Medical Center   (South Korea)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Carcinoma of unknown primary sites; Diagnosis; Imaging; Immunohistochemistry; Occult primary

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARBOPLATIN; CYTOKERATIN 20; CYTOKERATIN 7; ERLOTINIB; PACLITAXEL; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR PAX8; TUMOR MARKER;

BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL EVALUATION; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DISTANT METASTASIS; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERDISCIPLINARY COMMUNICATION; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGIST; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOLOGIST; REVIEW; IMAGE ENHANCEMENT; METHODOLOGY;

DIAGNOSTIC IMAGING; HUMANS; IMAGE ENHANCEMENT; NEOPLASMS, UNKNOWN PRIMARY; PATHOLOGY, MOLECULAR;

MLCS; MLOWN;

EID: 84876038155     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9363     Document Type: Review

References (38)

1. Ettinger DS, Agulnik M, Cates JM, et al. NCCN clinical practice guidelines in oncology: occult primary. J Natl Compr Canc Netw 2011; 9:1358-1395
2. Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22(suppl 6):vi64-vi68
3. Pavlidis N, Fizazi K. Carcinoma of unknown primary (CUP). Crit Rev Oncol Hematol 2009; 69:271-278
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29
5. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45:8-30
6. National Institute for Health and Clinical Excellence website. Diagnosis and management of metastatic malignant disease of unknown primary origin (clinical guideline 104). www.nice.org.uk/CG104. Published July 10, 2010. Accessed October 16, 2012
7. Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet 2012; 379:1428-1435
8. Taylor MB, Bromham NR, Arnold SE. Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines. Br J Radiol 2012; 85:661-671
9. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer 2007; 43:2026-2036
10. Varadhachary GR. Carcinoma of unknown primary: focused evaluation. J Natl Compr Canc Netw 2011; 9:1406-1412
11. Greco FA, Oien K, Erlander M, et al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol 2012; 23:298-304
12. Varadhachary GR, Greco FA. Overview of patient management and future directions in unknown primary carcinoma. Semin Oncol 2009; 36:75-80
13. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol 2009; 36:8-37
14. Hainsworth JD, Fizazi K. Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol 2009; 36:44-51
15. National Comprehensive Cancer Network website. NCCN clinical practice guidelines in oncology: occult primary (cancer of unknown primary [CUP]) version I. www.nccn.org. Accessed November 5, 2012
16. Latief KH, White CS, Protopapas Z, Attar S, Krasna MJ. Search for a primary lung neoplasm in patients with brain metastasis: is the chest radiograph sufficient? AJR 1997; 168:1339-1344
17. Ambrosini V, Nanni C, Rubello D, et al. 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin. Radiol Med (Torino) 2006; 111:1146-1155
18. Roh JL, Kim JS, Lee JH, et al. Utility of combined (18)F- fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncol 2009; 45:218-224
19. Keller F, Psychogios G, Linke R, et al. Carcinoma of unknown primary in the head and neck: comparison between positron emission tomography (PET) and PET/CT. Head Neck 2011; 33:1569-1575
20. Greco FA, Hainsworth JD. Cancer of unknown primary site. In: DeVita VT Jr., Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2008:2363-2387
21. Sève P, Billotey C, Broussolle C, Dumontet C, Mackey Jr. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109:292-299
22. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 2003; 39:1990-2005
23. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 2004; 100:1776-1785
24. Berner A, Lund-Iversen M, Nesland JM. Fine needle aspirations in oncology. Arkh Patol 2011; 73:21-26
25. Strojan P, Ferlito A, Medina JE, et al. Contempo-rary management of lymph node metastases from an unknown primary to the neck. Part I. A review of diagnostic approaches. Head Neck [Epub 2011 Oct 27]
26. Oct 27] 26. Francis IR, Cohan RH, McNulty NJ, et al. Multidetector CT of the liver and hepatic neoplasms: effect of multiphasic imaging on tumor conspicuity and vascular enhancement. AJR 2003; 180:1217-1224
27. Kim SY, Kim KW, Kim AY, et al. Bloodborne metastatic tumors to the gastrointestinal tract: CT findings with clinicopathologic correlation. AJR 2006; 186:1618-1626
28. Gu TF, Xiao XL, Sun F, Yin JH, Zhao H. Diagnostic value of whole body diffusion weighted imaging for screening primary tumors of patients with metastases. Chin Med Sci J 2008; 23:145-150
29. Chen C, Orel SG, Harris E, Schnall MD, Czerniecki BJ, Solin LJ. Outcome after treatment of patients with mammographically occult, magnetic resonance imaging-detected breast cancer presenting with axillary lymphadenopathy. Clin Breast Cancer 2004; 5:72-77
30. Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome. Ann Intern Med 1986; 104:547-553
31. Molina R, Bosch X, Auge JM, et al. Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. Tumour Biol 2012; 33:463-474
32. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician 2003; 68:1075-1082
33. Duraker N, Hot S, Polat Y, Hobek A, Gencler N, Urhan N. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 2007; 95:142-147
34. Gadducci A, Cosio S, Carpi A, Nicolini A, Genazzani AR. Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother 2004; 58:24-38
35. Varadhachary GR, Talantov D, Raber MN, et al. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 2008; 26:4442-4448
36. Hainsworth JD, Spigel DR, Thompson DS, et al. Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist 2009; 14:1189-1197
37. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 2007; 25:1747-1752
38. Kim KW, Lee JM, Choi BI. Assessment of the treatment response of HCC. Abdom Imaging 2011; 36:300-314